NASDAQ:DXCM - Dexcom Stock Price, Price Target & More

Dexcom trades on the NASDAQ under the ticker symbol "DXCM."

Dexcom (NASDAQ:DXCM) issued its quarterly earnings data on Wednesday, May, 2nd. The medical device company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.32). The medical device company had revenue of $184.40 million for the quarter, compared to analysts' expectations of $172.66 million. Dexcom had a negative net margin of 4.30% and a negative return on equity of 9.32%. The business's quarterly revenue was up 29.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.49) EPS. View Dexcom's Earnings History.

Dexcom is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Dexcom.

19 equities research analysts have issued 1 year price targets for Dexcom's stock. Their forecasts range from $40.00 to $100.00. On average, they expect Dexcom's share price to reach $69.7941 in the next twelve months. View Analyst Ratings for Dexcom.

Dexcom saw a drop in short interest in the month of April. As of April 13th, there was short interest totalling 12,600,819 shares, a drop of 10.9% from the March 30th total of 14,147,733 shares. Based on an average daily trading volume, of 1,326,047 shares, the days-to-cover ratio is presently 9.5 days. Approximately 14.9% of the shares of the company are short sold.

Some companies that are related to Dexcom include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Haemonetics (HAE), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).

News coverage about DXCM stock has trended somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dexcom earned a coverage optimism score of 0.18 on Accern's scale. They also gave media stories about the medical device company an impact score of 45.49 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Dexcom's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (6.15%), BlackRock Inc. (4.41%), JPMorgan Chase & Co. (2.94%), OppenheimerFunds Inc. (1.70%), Franklin Resources Inc. (1.33%) and Point72 Asset Management L.P. (1.11%). Company insiders that own Dexcom stock include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jonathan T Md Lord, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for Dexcom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Russell Investments Group Ltd., Massachusetts Financial Services Co. MA, Baillie Gifford & Co., Compagnie Lombard Odier SCmA, Thornburg Investment Management Inc., Allianz Asset Management GmbH and Blair William & Co. IL. Company insiders that have sold Dexcom company stock in the last year include Andrew K Balo, Barbara Kahn, Jacob Steven Leach, Jay S Skyler, Kevin R Sayer, Mark G Foletta, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for Dexcom.

DXCM stock was acquired by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Point72 Asset Management L.P., Neuberger Berman Group LLC, Federated Investors Inc. PA, JPMorgan Chase & Co., Columbus Circle Investors, Frontier Capital Management Co. LLC and Chicago Capital LLC. View Insider Buying and Selling for Dexcom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $86.24.

Dexcom has a market capitalization of $7.63 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Dexcom employs 2,990 workers across the globe.

Dexcom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]